Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-16A PET/CT in Solid Tumors
NCT06429891Recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of 89Zr-16A in gastric cancer (GC) and solid tumor. Primary endpoint: Standardized Uptake Value at 2 years. Started Aug 2024; status: recruiting.
02
Drugs
89Zr-16A
03
Conditions
gastric cancer (GC)solid tumor
Beyond the preview
Go deeper on NCT06429891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429891.